Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
I don't see how you can talk about aducanumab setting a new standard and easing the way for other anti-Alzheimer's drugs to follow suit.

What I was suggesting is aducanumab sets a a very low standard by the FDA, many other candidates think they can do far better for AD patients both in safety and efficacy. Meanwhile medicare and insurers will have started getting used to paying $56K / yr for treatment, priming the pump for the next better drug to take that market share.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.